Li Yue serves as Independent Director of the Company. Mr. Li has about 20 years of experience in M&A and capital markets in China and the U.S. Mr. Li currently is a Managing Director at PagodaTree Partners, a private equity company with a focus on healthcare in Beijing. Prior to PagodaTree, he was a senior executive at a major conglomerate in China where he successfully closed $2 billion M&A transactions in healthcare and insurance areas. Previously, Mr. Li spent 8 years in Deloitte, as a director of financial advisory services in Beijing and capital markets in New York. His key clients included Merrill Lynch, Blackrock, KKR etc. In his early career, Mr. Li served for top tier financial institutions such as Credit Suisse and Fannie Mae, responsible for asset allocation strategy and risk management for multibillion USD portfolios. Mr. Li received Master’s degree from the Olin School of Business at Washington University in 2000 and a Bachelor of Engineering from Tianjin University in 1996. He is a CFA charter holder. Mr. Li is qualified to serve as a director because of his extensive investment and executive level management experience.
As the Independent Director of Avalon GloboCare Corp, the total compensation of Li Yue at Avalon GloboCare Corp is $172,745. There are 12 executives at Avalon GloboCare Corp getting paid more, with Lu Wenzhao having the highest compensation of $4,047,220.
Li Yue is 46, he's been the Independent Director of Avalon GloboCare Corp since 2019. There are 9 older and 3 younger executives at Avalon GloboCare Corp. The oldest executive at Avalon GloboCare Corp is Wilbert Tauzin, 76, who is the Director.
Yue's mailing address filed with the SEC is C/O AVALON GLOBOCARE CORP.,, 4400 ROUTE 9, SUITE 3100, FREEHOLD,, NJ, 07728.
Over the last 8 years, insiders at Avalon GloboCare Corp have traded over $2,500,000 worth of Avalon GloboCare Corp stock and bought 898,876 units worth $1,418,962 . The most active insiders traders include Wenzhao Lu, Luisa Ingargiola y Steven Andrew Sanders. On average, Avalon GloboCare Corp executives and independent directors trade stock every 157 days with the average trade being worth of $446,629. The most recent stock trade was executed by Wenzhao Lu on 1 April 2020, trading 645,161 units of AVCO stock currently worth $1,000,000.
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Avalon GloboCare Corp executives and other stock owners filed with the SEC include: